Going concern and liquidity shortfall
Management disclosed that existing cash may not fund operations beyond one year without additional revenue or financing.
- Scope
- Operating runway and ability to fund commercialization and R&D
- Materiality
- high
Invivyd, Inc.
Invivyd, Inc. is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing monoclonal antibody therapies for the prevention and treatment of serious viral infectious diseases. Its first authorized product, PEMGARDA (pemivibart), is designed to provide ongoing protection against SARS-CoV-2 despite viral evolution, and the company is also advancing additional product candidates such as VYD2311.
−98,2 %
+110,5 %
7.24
6.50
| % | |
|---|---|
| Authorized product sales | 85% Sales of PEMGARDA in the U.S. through specialty distributors and direct accounts. |
| Pipeline development | 10% Discovery, preclinical, and clinical development of next-generation mAb candidates such as VYD2311. |
| Commercial support and distribution | 5% Third-party logistics, customer service, and distribution infrastructure supporting product delivery. |
Invivyd sells primarily into the U.S. healthcare channel, with PEMGARDA purchased by third-party specialty distributors...
- Specialty distributorsprimary
Buy PEMGARDA for resale and distribution to sites of care; important because they handle channel access and logistics.
- Infusion centersprimary
Purchase directly or through distributors to administer PEMGARDA in outpatient settings.
- Healthcare providers and provider institutionsprimary
Hospitals, clinics, and provider groups that buy and administer the product for eligible patients.
- Payers and reimbursement stakeholderssecondary
Not direct product customers, but they determine net realization through coverage and billing rules.
Invivyd’s commercial revenue is currently concentrated in the United States, where PEMGARDA is sold under a traditional...
- •U.S. is the only disclosed revenue market for PEMGARDA
- •Sales flow through specialty distributors and direct healthcare accounts
- •Commercial sites include infusion centers, clinics, and provider institutions
- •International activity is mainly IP/trademark coverage, not disclosed revenue
- •Geographic concentration increases dependence on U.S. regulatory and reimbursement access
Invivyd’s strategy is to build a commercial franchise around PEMGARDA while advancing next-generation monoclonal...
01
Expand PEMGARDA commercializationshort-term
Current revenue depends on adoption of the first authorized product and access to sites of care.
02
Build internal commercial capabilitiesshort-term
The company needs sales, marketing, and market access capacity to support product uptake and future launches.
03
Advance next-generation pipeline assetsmedium-term
Pipeline diversification reduces dependence on a single authorized product and addresses viral evolution risk.
04
Secure manufacturing and supply resiliencemedium-term
Commercial continuity depends on third-party CDMO access and uninterrupted supply of biologic product.
Invivyd faces the classic risks of an early commercial-stage biotech: dependence on a single authorized product,...
Single-product concentration
Current product revenue is tied primarily to PEMGARDA, so demand or reimbursement weakness would directly hit sales.
- Scope
- Revenue concentration
- Materiality
- high
Manufacturing and supply chain dependence
The company relies on third-party manufacturers and CDMOs, including foreign contract manufacturers that may face trade or regulatory restrictions.
- Scope
- Supply continuity, cost, and launch timing
- Materiality
- high
Regulatory and scientific obsolescence
Antibody effectiveness can be undermined by viral evolution, which can reduce clinical and commercial relevance.
- Scope
- Product efficacy and authorization durability
- Materiality
- high
Nasdaq listing compliance
The company previously received a minimum bid price deficiency notice and could face future listing pressure if market conditions weaken.
- Scope
- Capital markets access and trading liquidity
- Materiality
- medium
Revenue recognition and variable consideration
Can materially change reported product revenue and gross-to-net deductions
Channel inventory and reserves
Affects revenue timing and period-to-period comparability
Going-concern assessment
Signals financing risk and uncertainty in future operating plans
R&D and third-party manufacturing costs
Can create lumpy operating expense patterns and estimate sensitivity
Innoviva, Inc.
INVA · Pharmaceutical Preparations
Innventure, Inc.
INV · Blank Checks
Inotiv, Inc.
NOTVQ · Services-Commercial Physical & Biological Research
INOVIO PHARMACEUTICALS, INC.
INO · Pharmaceutical Preparations
INOVIO Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases.
InnovAge Holding Corp.
INNV · Services-Health Services
SKINVISIBLE, INC.
SKVI · Pharmaceutical Preparations
: 28.4.2026